Show simple item record

canSAR: update to the cancer translational research and drug discovery knowledgebase.

dc.contributor.authorCoker, EA
dc.contributor.authorMitsopoulos, C
dc.contributor.authorTym, JE
dc.contributor.authorKomianou, A
dc.contributor.authorKannas, C
dc.contributor.authorDi Micco, P
dc.contributor.authorVillasclaras Fernandez, E
dc.contributor.authorOzer, B
dc.contributor.authorAntolin, AA
dc.contributor.authorWorkman, P
dc.contributor.authorAl-Lazikani, B
dc.date.accessioned2019-01-24T16:12:51Z
dc.date.issued2019-01-08
dc.identifier.citationNucleic acids research, 2019, 47 (D1), pp. D917 - D922
dc.identifier.issn0305-1048
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3016
dc.identifier.eissn1362-4962
dc.identifier.doi10.1093/nar/gky1129
dc.description.abstractcanSAR (http://cansar.icr.ac.uk) is a public, freely available, integrative translational research and drug discovery knowlegebase. canSAR informs researchers to help solve key bottlenecks in cancer translation and drug discovery. It integrates genomic, protein, pharmacological, drug and chemical data with structural biology, protein networks and unique, comprehensive and orthogonal 'druggability' assessments. canSAR is widely used internationally by academia and industry. Here we describe major enhancements to canSAR including new and expanded data. We also describe the first components of canSARblack-an advanced, responsive, multi-device compatible redesign of canSAR with a question-led interface.
dc.formatPrint
dc.format.extentD917 - D922
dc.languageeng
dc.language.isoeng
dc.publisherOXFORD UNIV PRESS
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectAntineoplastic Agents
dc.subjectProtein Interaction Mapping
dc.subjectProtein Conformation
dc.subjectUser-Computer Interface
dc.subjectKnowledge Bases
dc.subjectDrug Discovery
dc.subjectTranslational Medical Research
dc.subjectDatabases, Pharmaceutical
dc.titlecanSAR: update to the cancer translational research and drug discovery knowledgebase.
dc.typeJournal Article
dcterms.dateAccepted2018-11-26
rioxxterms.versionofrecord10.1093/nar/gky1129
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2019-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfNucleic acids research
pubs.issueD1
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Computational Biology and Chemogenomics
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Computational Biology and Chemogenomics
pubs.publication-statusPublished
pubs.volume47
pubs.embargo.termsNo embargo
icr.researchteamComputational Biology and Chemogenomics
dc.contributor.icrauthorMitsopoulos, Konstantinos
dc.contributor.icrauthorWorkman, Paul
dc.contributor.icrauthorAl-Lazikani, Bissan


Files in this item

Thumbnail
Name:
gky1129.pdf
Size:
1.957Mb
Format:
PDF
Description:
Published version
View/Open

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0